# Qianglian Zhichuang (Beijing) Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qianglian-zhichuang-beijing-technology-co

- Industry: Healthcare
- Headquarters: Beijing, China
- Website: www.unionstrongtech.com
- Total disclosed funding: $44M
- Latest round: Series D (Oct 21, 2024)
- Investors on record: 17

## About

Based in Beijing, China and established in 2016, Qianglian Zhichuang (Beijing) Technology Co., Ltd. is a healthcare company that provides cerebrovascular disease diagnoses services. The company has cooperated with People's Liberation Army General Hospital, Capital Medical University, Tsinghua University and other hospitals and universities. It has acquired more than 100 patents and was rated as Specialized, Refined, Featured and Original SME and National High-tech Enterprise. In October 2024, Union Strong raised approximately CNY 100 million in series D+ funding from Beijing Medical and Health and E-Town International Industrial Investment.

Qianglian Zhichuang has developed an intelligent stroke diagnosis and treatment platform, providing intelligent auxiliary diagnosis and treatment tools for hemorrhagic stroke and ischemic stroke. Specific products include intracranial aneurysm surgery planning software UKnow, intracranial aneurysm auxiliary assessment software UKnow Risk, medical technology service platform USearch and more. The company has also established the case database, providing data entry and audit services, as well as clinical research and clinical trial services.

The company generates revenue by providing intelligent diagnosis and treatment products, technology platforms and scientific research services in the field of cerebrovascular diseases.

The company will use the series D+ funding to develop and innovate products, technologies, and promote the clinical application of intelligent solutions for intracranial aneurysm surgery.

## Funding rounds

- Series D, Oct 21, 2024, $14M — E-Town International Industrial Investment, Shunxi Fund
- Series D, Dec 28, 2023, $14M — Yantai Tongju Investment Management
- Series C, Jan 31, 2022, $16M — Hong Shan, Juffett Capital, Poly Capital, Probe New Medical Fund, Nuoyu Capital
- Series C, Sep 14, 2021 — Hong Shan, YuanBio Venture, Sunland Capital, BioTrack Capital, Green Waters Fund
- Series B, Feb 8, 2021 — YuanBio Venture, Lenovo Capital and Incubator Group, BioTrack Capital
- Series B, Oct 12, 2020 — Chiron Ventures, Sunland Capital
- Series A, Apr 17, 2019 — Legend Star, Topping Capital
- Angel, Mar 1, 2016 — AnlongMed Investment

## Investors

- AnlongMed Investment — Angel
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series A
- Topping Capital (https://capitalatlas.ai/funds/topping-capital) — Series A
- Chiron Ventures — Series B
- Sunland Capital — Series B, Series C
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B, Series C
- Lenovo Capital and Incubator Group (https://capitalatlas.ai/funds/lenovo-capital-and-incubator-group) — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B, Series C
- Hong Shan — Series C
- Green Waters Fund — Series C
- Juffett Capital (https://capitalatlas.ai/funds/juffett-capital) — Series C
- Poly Capital (https://capitalatlas.ai/funds/poly-capital) — Series C
- Probe New Medical Fund — Series C
- Nuoyu Capital — Series C
- Yantai Tongju Investment Management (https://capitalatlas.ai/funds/yantai-tongju-investment-management) — Series D
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series D
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series D